85 related articles for article (PubMed ID: 27672056)
1. Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences.
Valla M; Vatten LJ; Engstrøm MJ; Haugen OA; Akslen LA; Bjørngaard JH; Hagen AI; Ytterhus B; Bofin AM; Opdahl S
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1625-1634. PubMed ID: 27672056
[TBL] [Abstract][Full Text] [Related]
2. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
[TBL] [Abstract][Full Text] [Related]
3. Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program.
Ellingjord-Dale M; Vos L; Hjerkind KV; Hjartåker A; Russnes HG; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1736-1744. PubMed ID: 28877889
[No Abstract] [Full Text] [Related]
4. Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women.
Horn J; Opdahl S; Engstrøm MJ; Romundstad PR; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Åsvold BO
Cancer Causes Control; 2014 Jul; 25(7):881-9. PubMed ID: 24789514
[TBL] [Abstract][Full Text] [Related]
5. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
6. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
7. Quantifying tumour vascularity in non-luminal breast cancers.
Kraby MR; Opdahl S; Akslen LA; Bofin AM
J Clin Pathol; 2017 Sep; 70(9):766-774. PubMed ID: 28249942
[TBL] [Abstract][Full Text] [Related]
8. Differences in Breast Cancer Survival by Molecular Subtypes in the United States.
Howlader N; Cronin KA; Kurian AW; Andridge R
Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):619-626. PubMed ID: 29593010
[No Abstract] [Full Text] [Related]
9. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
10. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
11. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades.
Haque R; Ahmed SA; Inzhakova G; Shi J; Avila C; Polikoff J; Bernstein L; Enger SM; Press MF
Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1848-55. PubMed ID: 22989461
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
14. Long term trends of breast cancer incidence according to proliferation status.
Klæstad E; Opdahl S; Raj SX; Bofin AM; Valla M
BMC Cancer; 2022 Dec; 22(1):1340. PubMed ID: 36544164
[TBL] [Abstract][Full Text] [Related]
15. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
16. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.
Nielsen TO; Jensen MB; Burugu S; Gao D; Jørgensen CL; Balslev E; Ejlertsen B
Clin Cancer Res; 2017 Feb; 23(4):946-953. PubMed ID: 27601592
[No Abstract] [Full Text] [Related]
17. 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Gerstenhauer M; Brockhoff G; Ortmann O
Breast Cancer Res Treat; 2015 Oct; 153(3):647-58. PubMed ID: 26369534
[TBL] [Abstract][Full Text] [Related]
18. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.
Lee Y; Kang E; Lee AS; Baek H; Kim EK; Park SY; Kim JH; Kim YJ; Kim SH; Kim IA; Eom KY; Kim SW
Breast Cancer Res Treat; 2015 May; 151(1):183-90. PubMed ID: 25893592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
